PubMed

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis.

White B, Moore WC, Wigley FM, Xiao HQ, Wise RA.

Ann Intern Med. 2000 Jun 20;132(12):947-54.PMID: 10858177 [PubMed - indexed for MEDLINE]Related articlesFree article

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.

Beretta L, Caronni M, Raimondi M, Ponti A, Viscuso T, Origgi L, Scorza R.

Clin Rheumatol. 2007 Feb;26(2):168-72. Epub 2006 Apr 14.PMID: 16614793 [PubMed - indexed for MEDLINE]Related articles

Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.

Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, FitzGerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfield NF, Mubarak K, Molitor J, Tashkin DP; Scleroderma Lung Study Group.

Arthritis Rheum. 2005 Feb;52(2):592-600.PMID: 15692967 [PubMed - indexed for MEDLINE]Related articlesFree article

Cyclophosphamide versus placebo in scleroderma lung disease.

Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M; Scleroderma Lung Study Research Group.

N Engl J Med. 2006 Jun 22;354(25):2655-66.PMID: 16790698 [PubMed - indexed for MEDLINE]Related articlesFree article

Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome.

Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, Haslam PL, Vassilakis DA, Black CM, du Bois RM.

Am J Respir Crit Care Med. 2002 Jun 15;165(12):1581-6.PMID: 12070056 [PubMed - indexed for MEDLINE]Related articlesFree article

Cyclophosphamide reduces neutrophilic alveolitis in patients with scleroderma lung disease: a retrospective analysis of serial bronchoalveolar lavage investigations.

Kowal-Bielecka O, Kowal K, Rojewska J, Bodzenta-Lukaszyk A, Siergiejko Z, Sierakowska M, Sierakowski S.

Ann Rheum Dis. 2005 Sep;64(9):1343-6.PMID: 16100339 [PubMed - indexed for MEDLINE]Related articlesFree article

Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease.

Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, Clements P, Chung J, Elashoff RM, Suh R, Smith EA, Furst DE, Tashkin DP; Scleroderma Lung Study Research Group.

Am J Respir Crit Care Med. 2008 Jan 1;177(1):91-8. Epub 2007 Sep 27.PMID: 17901414 [PubMed - indexed for MEDLINE]Related articlesFree article

Persistence of abnormal bronchoalveolar lavage findings after cyclophosphamide treatment in scleroderma patients with interstitial lung disease.

Mittoo S, Wigley FM, Wise R, Xiao H, Hummers L.

Arthritis Rheum. 2007 Dec;56(12):4195-202.PMID: 18050251 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.

Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI.

Am J Med. 1990 May;88(5):470-6.PMID: 2337105 [PubMed - indexed for MEDLINE]Related articles

Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.

Ostojic P, Damjanov N.

Clin Rheumatol. 2006 Nov;25(6):819-21. Epub 2006 Jan 27.PMID: 16440134 [PubMed - indexed for MEDLINE]Related articles

Determinants of pulmonary function improvement in patients with scleroderma and interstitial lung disease.

Tzelepis GE, Plastiras SC, Karadimitrakis SP, Vlachoyiannopoulos PG.

Clin Exp Rheumatol. 2007 Sep-Oct;25(5):734-9.PMID: 18078622 [PubMed - indexed for MEDLINE]Related articles

Evaluation and management of alveolitis and interstitial lung disease in scleroderma.

Latsi PI, Wells AU.

Curr Opin Rheumatol. 2003 Nov;15(6):748-55. Review.PMID: 14569205 [PubMed - indexed for MEDLINE]Related articles

Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.

Plastiras SC, Karadimitrakis SP, Ziakas PD, Vlachoyiannopoulos PG, Moutsopoulos HM, Tzelepis GE.

Arthritis Rheum. 2006 Aug 15;55(4):598-602.PMID: 16874782 [PubMed - indexed for MEDLINE]Related articlesFree article

Fibroblast chemotactic response elicited by native bronchoalveolar lavage fluid from patients with fibrosing alveolitis.

Behr J, Adelmann-Grill BC, Krombach F, Beinert T, Schwaiblmair M, Fruhmann G.

Thorax. 1993 Jul;48(7):736-42.PMID: 8153923 [PubMed - indexed for MEDLINE]Related articlesFree article

A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.

Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, Roberts C, Desai S, Herrick AL, McHugh NJ, Foley NM, Pearson SB, Emery P, Veale DJ, Denton CP, Wells AU, Black CM, du Bois RM.

Arthritis Rheum. 2006 Dec;54(12):3962-70.PMID: 17133610 [PubMed - indexed for MEDLINE]Related articlesFree article

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma.

Davas EM, Peppas C, Maragou M, Alvanou E, Hondros D, Dantis PC.

Clin Rheumatol. 1999;18(6):455-61.PMID: 10638770 [PubMed - indexed for MEDLINE]Related articles

Carbon monoxide diffusing capacity as predictor of outcome in systemic sclerosis.

Peters-Golden M, Wise RA, Hochberg MC, Stevens MB, Wigley FM.

Am J Med. 1984 Dec;77(6):1027-34.PMID: 6507456 [PubMed - indexed for MEDLINE]Related articles

Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study.

Steen VD, Lanz JK Jr, Conte C, Owens GR, Medsger TA Jr.

Arthritis Rheum. 1994 Sep;37(9):1290-6.PMID: 7945491 [PubMed - indexed for MEDLINE]Related articles

Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease.

Liossis SN, Bounas A, Andonopoulos AP.

Rheumatology (Oxford). 2006 Aug;45(8):1005-8. Epub 2006 Feb 20.PMID: 16490756 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluation and management of pulmonary fibrosis in scleroderma.

White B.

Curr Rheumatol Rep. 2002 Apr;4(2):108-12. Review.PMID: 11890875 [PubMed - indexed for MEDLINE]Related articles